StreetInsider.com News Articles

Form EFFECT Decoy Therapeutics Inc.

Mon, 19 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261019/27200183.html

Form 424B3 Decoy Therapeutics Inc.

Fri, 16 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261016/27198000.html

Decoy Therapeutics (DCOY) files for 2.37M share offering by selling stockholders

Wed, 07 Oct 2026 17:01:30 -0400

Decoy Therapeutics (NASDAQ: DCOY) on Wednesday filed for up to 2,368,868 share offering by selling stockholders.

Decoy Therapeutics (DCOY) files for 2.37M share offering by selling stockholders

Wed, 07 Oct 2026 17:01:30 -0400

Decoy Therapeutics (NASDAQ: DCOY) on Wednesday filed for up to 2,368,868 share offering by selling stockholders.

Form S-1 Decoy Therapeutics Inc.

Wed, 07 Oct 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20261007/27161872.html

Decoy Therapeutics to Present at The Small Cap Showcase

Wed, 30 Sep 2026 08:30:00 -0400

CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at The Small Cap Showcase, taking place Thursday, October 1, 2026 in New York City.

Mr. Pierce will deliver a corporate overview and participate in one-on-one meetings with investors during the conference.

Details of the presentation are as follows:

Date: Thursday, October 1, 2026
Time: 11:30 a.m. ET
Location: New York,

Decoy Therapeutics to Present at The Small Cap Showcase

Wed, 30 Sep 2026 08:30:00 -0400

Mr. Pierce will deliver a corporate overview and participate in one-on-one meetings with investors during the conference.

Details of the presentation are as follows:

Date: Thursday, October 1, 2026
Time: 11:30 a.m. ET
Location: New York,

Decoy Therapeutics shares preclinical data for weekly coronavirus drug

Tue, 29 Sep 2026 07:30:30 -0400

Decoy Therapeutics, Inc. (NASDAQ: DCOY) announced preclinical pharmacokinetic data on Sept. 29 showing that a single intranasal dose of its DCOY-CoV drug candidate maintained therapeutic concentrations in upper respiratory mucosal tissue and lung tissue for up to seven days.

The data were presented by Chief Technology Officer Dr. Michael Lipp at the Boulder Peptide Symposium's Peptide Showcase in Napa Valley, California.

DCOY-CoV is designed to target five endemic human coronaviruses — OC43, 229E, NL63, HKU1, and SARS-CoV-2 — using the company's IMP³ACT™ platform, which combines lipid- and peptide-conjugate engineering. The program is intended for high-risk populations, including an estimated 20 million immunocompromised

Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program

Tue, 29 Sep 2026 07:30:00 -0400

Once-Weekly Intranasal Potential: Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue.

Addressing Endemic Coronaviruses: DCOY-CoV is designed to protect against endemic human coronaviruses (OC43, 229E, NL63, HKU1, and SARS-CoV-2), in people at high risk of serious illness including the more than 20 million high-risk immunocompromised and 15 million COPD patients

Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program

Tue, 29 Sep 2026 07:30:00 -0400

Once-Weekly Intranasal Potential: Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue.

Addressing Endemic Coronaviruses: DCOY-CoV is designed to protect against endemic human coronaviruses (OC43, 229E, NL63, HKU1, and SARS-CoV-2), in people at high risk of serious illness including the more than 20 million high-risk immunocompromised and 15 million COPD patients

Form 8-K Decoy Therapeutics Inc. For: Sep 22

Wed, 23 Sep 2026 17:02:00 -0400
si-local-file:///var/storage/secattach/20260923/27097329.html

Decoy Therapeutics corrects warrant exercisability in inducement deal

Tue, 22 Sep 2026 18:16:12 -0400

Decoy Therapeutics, Inc. (NASDAQ: DCOY) issued a correction to a press release dated September 22, 2026, related to its warrant inducement transaction.
The original release incorrectly stated that new unregistered warrants to purchase up to 2,368,868 shares of the company's common stock would become exercisable upon receipt of stockholder approval. The company clarified that the warrants are not subject to stockholder approval and will become exercisable immediately upon issuance. The warrants will expire five years from the date of issuance.
All other terms of the original warrant inducement transaction remain unchanged, according to the company's statement.

Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release

Tue, 22 Sep 2026 18:14:00 -0400

HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction.

Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release

Tue, 22 Sep 2026 18:14:00 -0400

HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction.

Decoy Therapeutics raises $3.85M via warrant inducement deal

Tue, 22 Sep 2026 12:52:43 -0400

Decoy Therapeutics, Inc. (NASDAQ: DCOY) has entered into a warrant inducement agreement with an existing institutional investor, involving the immediate exercise of 1,184,434 Series B Milestone Warrants at a reduced price of $3.25 per share, according to a company statement.
The transaction is expected to generate gross cash proceeds of approximately $3.85 million before placement agent fees and other expenses. The company said it intends to use net proceeds for working capital and general corporate purposes.
The Series B Milestone Warrants were originally issued on June 29, 2026. As part of the agreement, the exercise price of the company's outstanding Series A

Decoy Therapeutics raises $3.85M via warrant inducement deal

Tue, 22 Sep 2026 12:52:43 -0400

Decoy Therapeutics, Inc. (NASDAQ: DCOY) has entered into a warrant inducement agreement with an existing institutional investor, involving the immediate exercise of 1,184,434 Series B Milestone Warrants at a reduced price of $3.25 per share, according to a company statement.
The transaction is expected to generate gross cash proceeds of approximately $3.85 million before placement agent fees and other expenses. The company said it intends to use net proceeds for working capital and general corporate purposes.
The Series B Milestone Warrants were originally issued on June 29, 2026. As part of the agreement, the exercise price of the company's outstanding Series A

Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules

Tue, 22 Sep 2026 12:50:00 -0400

HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of the Series B Milestone Warrants to purchase shares of the Company's common stock, for a total of

Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules

Tue, 22 Sep 2026 12:50:00 -0400

HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of the Series B Milestone Warrants to purchase shares of the Company's common stock, for a total of

Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals

Tue, 22 Sep 2026 10:31:55 -0400

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ: VKTX) is pushing its VK2735 obesity program toward Phase 3 while exploring less-frequent maintenance dosing; NeOnc Technologies Holdings (NASDAQ: NTHI) is advancing its NEO100 brain-cancer program after encouraging Phase 2a results; Decoy Therapeutics (NASDAQ: DCOY) is expanding its antiviral platform into high-consequence viruses including Ebola; and Greenland Mines Ltd. (NASDAQ: GRML) is seeking to more than double its exploration footprint at the Sarfartoq rare-earth district.

Viking Therapeutics

The obesity-drug race is rapidly shifting

Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals

Tue, 22 Sep 2026 10:31:55 -0400

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ: VKTX) is pushing its VK2735 obesity program toward Phase 3 while exploring less-frequent maintenance dosing; NeOnc Technologies Holdings (NASDAQ: NTHI) is advancing its NEO100 brain-cancer program after encouraging Phase 2a results; Decoy Therapeutics (NASDAQ: DCOY) is expanding its antiviral platform into high-consequence viruses including Ebola; and Greenland Mines Ltd. (NASDAQ: GRML) is seeking to more than double its exploration footprint at the Sarfartoq rare-earth district.

Viking Therapeutics

The obesity-drug race is rapidly shifting

Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals

Tue, 22 Sep 2026 10:31:55 -0400

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ: VKTX) is pushing its VK2735 obesity program toward Phase 3 while exploring less-frequent maintenance dosing; NeOnc Technologies Holdings (NASDAQ: NTHI) is advancing its NEO100 brain-cancer program after encouraging Phase 2a results; Decoy Therapeutics (NASDAQ: DCOY) is expanding its antiviral platform into high-consequence viruses including Ebola; and Greenland Mines Ltd. (NASDAQ: GRML) is seeking to more than double its exploration footprint at the Sarfartoq rare-earth district.

Viking Therapeutics

The obesity-drug race is rapidly shifting

Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals

Tue, 22 Sep 2026 10:31:55 -0400

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ: VKTX) is pushing its VK2735 obesity program toward Phase 3 while exploring less-frequent maintenance dosing; NeOnc Technologies Holdings (NASDAQ: NTHI) is advancing its NEO100 brain-cancer program after encouraging Phase 2a results; Decoy Therapeutics (NASDAQ: DCOY) is expanding its antiviral platform into high-consequence viruses including Ebola; and Greenland Mines Ltd. (NASDAQ: GRML) is seeking to more than double its exploration footprint at the Sarfartoq rare-earth district.

Viking Therapeutics

The obesity-drug race is rapidly shifting

Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals

Tue, 22 Sep 2026 10:31:55 -0400

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ: VKTX) is pushing its VK2735 obesity program toward Phase 3 while exploring less-frequent maintenance dosing; NeOnc Technologies Holdings (NASDAQ: NTHI) is advancing its NEO100 brain-cancer program after encouraging Phase 2a results; Decoy Therapeutics (NASDAQ: DCOY) is expanding its antiviral platform into high-consequence viruses including Ebola; and Greenland Mines Ltd. (NASDAQ: GRML) is seeking to more than double its exploration footprint at the Sarfartoq rare-earth district.

Viking Therapeutics

The obesity-drug race is rapidly shifting

Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals

Tue, 22 Sep 2026 10:31:55 -0400

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ: VKTX) is pushing its VK2735 obesity program toward Phase 3 while exploring less-frequent maintenance dosing; NeOnc Technologies Holdings (NASDAQ: NTHI) is advancing its NEO100 brain-cancer program after encouraging Phase 2a results; Decoy Therapeutics (NASDAQ: DCOY) is expanding its antiviral platform into high-consequence viruses including Ebola; and Greenland Mines Ltd. (NASDAQ: GRML) is seeking to more than double its exploration footprint at the Sarfartoq rare-earth district.

Viking Therapeutics

The obesity-drug race is rapidly shifting

Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals

Tue, 22 Sep 2026 10:31:55 -0400

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ: VKTX) is pushing its VK2735 obesity program toward Phase 3 while exploring less-frequent maintenance dosing; NeOnc Technologies Holdings (NASDAQ: NTHI) is advancing its NEO100 brain-cancer program after encouraging Phase 2a results; Decoy Therapeutics (NASDAQ: DCOY) is expanding its antiviral platform into high-consequence viruses including Ebola; and Greenland Mines Ltd. (NASDAQ: GRML) is seeking to more than double its exploration footprint at the Sarfartoq rare-earth district.

Viking Therapeutics

The obesity-drug race is rapidly shifting